BioSpace News Archive

Seagen and Pfizer are in early-stage talks over a potential acquisition that could exceed $30 billion.

In its 2022 financial report Monday, uniQure provided updates on the progress of its Huntington’s disease and ALS programs.

The hits kept coming for the sickle cell disease space last week as the FDA placed a full clinical hold on Fulcrum Therapeutics’ Investigational New Drug application FTX-6058.

Senate Bill 1162, a law requiring employers to include pay ranges in all job advertisements, went into effect in California January 1. Here’s how employers are responding.

Billy Dunn, director of the FDA’s Office of Neuroscience, is stepping down from his post to “explore other opportunities,” according to an internal FDA e-mail.

ALS is the 5,000-piece jigsaw puzzle of the therapeutic world. As the regulatory edges come together, new research pieces are also connecting.

Telix Pharmaceuticals Limited announces its financial results for the financial year ended 31 December 2022.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of David Lawrence as Chief Financial Officer, effective as of March 1st, 2023.

Priothera announced that it received clearance from the Pharmaceuticals and Medical Devices Agency in Japan for the pivotal global MO-TRANS Phase 3 study evaluating mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic cell transplant.

AbbVie announced the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of upadacitinib for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.1-4